Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Comparable Insulin Glargine Biosimilar Could Help Relieve Diabetes Costs

October 27th 2025

By Skylar Jeremias

Article

Data Confirm Biosimilar Ranibizumab Non-Inferiority as Myopic CNVM Treatment

October 24th 2025

By Skylar Jeremias

Article

A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane, supporting cost-effective healthcare solutions.

Later-Line Therapies Drive Biosimilar Prescriptions in Turkish Rheumatology Practices

October 15th 2025

By Skylar Jeremias

Article

Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter disease duration, and female sex.

Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

October 14th 2025

By Skylar Jeremias

Article

A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants.

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

October 13th 2025

By Skylar Jeremias

Article

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 9th 2025

By Skylar Jeremias

Article

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions.

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 9th 2025

By Skylar Jeremias

Article

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

Global Biosimilars Market Sees Gains in Access and Pipeline Expansion

October 7th 2025

By Skylar Jeremias

Article

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market entries enhancing patient care.

Proposed Aflibercept Biosimilar Shows Comparable Safety, Efficacy in Phase 3 AMD Trial

October 2nd 2025

By Skylar Jeremias

Article

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular age-related macular degeneration (AMD), enhancing patient access.

Biosimilars News Roundup: September 2025

October 1st 2025

By Skylar Jeremias

Article

Biosimilar approvals surge in the US and Europe, enhancing access to denosumab and aflibercept therapies while driving significant health care savings.